The primary objective of the study is to collect additional safety data including the incidence rate of seizure and other specific Adverse Events (AEs) of interest from participants taking Fampyra in routine clinical practice. The secondary objectives of this study are to characterize utilization patterns of Fampyra in routine clinical practice, to assess the effectiveness of risk minimization measures as described in the risk management plan for Fampyra, to assess the change over time in participant self-reported evaluation of the physical and psychological impact of Multiple Sclerosis (MS) while taking Fampyra and to assess the change over time in physician assessment of walking ability in participants taking Fampyra (MS participants only).
Fampridine administered as prescribed in routine clinical practice. Biogen is not supplying drug for this study.
Ciudad Autonoma de Buanos Aires, Buenos Aires, Argentina
Rosario, Santa Fe Province, Argentina
Buenos Aires, Argentina
Córdoba, Argentina
Salta, Argentina